Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders
- University of Cambridge, United Kingdom
- University College London, United Kingdom
- McGill University, Canada
- King's College London, United Kingdom
- University of Miami Miller School of Medicine, United States
- Utrecht University, Netherlands
- University of Michigan, United States
- Columbia University, United States
- Gladstone Institutes, United States
- University of California, San Diego, United States
- University of Tübingen, Germany
- University of Sheffield, United Kingdom
Abstract
SARM1, a protein with critical NADase activity, is a central executioner in a conserved programme of axon degeneration. We report seven rare missense or in-frame microdeletion human SARM1 variant alleles in patients with amyotrophic lateral sclerosis (ALS) or other motor nerve disorders that alter the SARM1 auto-inhibitory ARM domain and constitutively hyperactivate SARM1 NADase activity. The constitutive NADase activity of these seven variants is similar to that of SARM1 lacking the entire ARM domain and greatly exceeds the activity of wild-type SARM1, even in the presence of nicotinamide mononucleotide (NMN), its physiological activator. This rise in constitutive activity alone is enough to promote neuronal degeneration in response to otherwise non-harmful, mild stress. Importantly, these strong gain-of-function alleles are completely patient-specific in the cohorts studied and show a highly significant association with disease at the single gene level. These findings of disease-associated coding variants that alter SARM1 function build on previously reported genome-wide significant association with ALS for a neighbouring, more common SARM1 intragenic single nucleotide polymorphism (SNP) to support a contributory role of SARM1 in these disorders. A broad phenotypic heterogeneity and variable age-of-onset of disease among patients with these alleles also raises intriguing questions about the pathogenic mechanism of hyperactive SARM1 variants.
Data availability
Genomic data was requested from a variety of previously published datasets from whom interested researchers can request access: Project MinE (https://www.projectmine.com/research/data-sharing/); Answer ALS (https://www.nygenome.org/als-consortium/); GENESIS (https://neuropathycommons.org/genetics/genesis-platform); UCL rare disease (neurology) dataset (available on request from Prof. Henry Houlden); HSP study (available on request from Dr. Rebecca Schüle); Lothian Birth Cohort (https://www.ed.ac.uk/lothian-birth-cohorts/data-access-collaboration). Further information about how to gain access to these datasets and any restrictions on who can gain access to the data is provided on these websites. The specifics of the datasets used are outlined in the Materials and Methods section, and are listed in Tables 1-4. Source data files of processed numerical data and raw blot images have been provided for Figures 2, 3, 4, 5, 6 and 7 and Figure 2 - figure supplement 2, Figure 3 - figure supplement 2 and Figure 6 - figure supplements 1 and 2.
Article and author information
Author details
Funding
Biotechnology and Biological Sciences Research Council (BB/S009582/1)
- Jonathan Gilley
- Oscar Jackson
- Michael P Coleman
EU Joint Programme – Neurodegenerative Disease Research
- Ammar Al-Chalabi
Robert Packard Center for ALS Research, Johns Hopkins University
- Jonathan Gilley
- Michael P Coleman
Wellcome Trust (216596/Z/19/Z)
- Johnathan Cooper-Knock
Wellcome Trust (220906/Z/20/Z)
- Jonathan Gilley
- Oscar Jackson
- Menelaos Pipis
- Mary M Reilly
- Michael P Coleman
National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712)
- Menelaos Pipis
- Mary M Reilly
National Institute of Neurological Disorders and Stroke (5R01NS072248-10 and 5R01NS105755-03)
- Matt C Danzi
- Stephan Züchner
Medical Research Council (MR/L501529/1 and MR/R024804/1)
- Ammar Al-Chalabi
Economic and Social Research Council (ES/L008238/1)
- Ammar Al-Chalabi
National Institute of Environmental Health Sciences (K23ES027221)
- Stephen A Goutman
Motor Neurone Disease Association
- Ammar Al-Chalabi
- Alfredo Iacoangeli
NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- Ammar Al-Chalabi
- Alfredo Iacoangeli
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: This is a retrospective study using anonymised data so specific consent was not obtained by the authors, but informed consent and consent to publish was obtained at each site that contributed patient information to this study in accordance with their local Institutional Review Boards (IRBs).
Copyright
© 2021, Gilley et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,324
- views
-
- 606
- downloads
-
- 49
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders
eLife 10:e70905.
https://doi.org/10.7554/eLife.70905
Further reading
-
- Computational and Systems Biology
- Genetics and Genomics
Root causal gene expression levels – or root causal genes for short – correspond to the initial changes to gene expression that generate patient symptoms as a downstream effect. Identifying root causal genes is critical towards developing treatments that modify disease near its onset, but no existing algorithms attempt to identify root causal genes from data. RNA-sequencing (RNA-seq) data introduces challenges such as measurement error, high dimensionality and non-linearity that compromise accurate estimation of root causal effects even with state-of-the-art approaches. We therefore instead leverage Perturb-seq, or high-throughput perturbations with single-cell RNA-seq readout, to learn the causal order between the genes. We then transfer the causal order to bulk RNA-seq and identify root causal genes specific to a given patient for the first time using a novel statistic. Experiments demonstrate large improvements in performance. Applications to macular degeneration and multiple sclerosis also reveal root causal genes that lie on known pathogenic pathways, delineate patient subgroups and implicate a newly defined omnigenic root causal model.
-
- Chromosomes and Gene Expression
- Genetics and Genomics
A new method for mapping torsion provides insights into the ways that the genome responds to the torsion generated by RNA polymerase II.
